文献速递神经肿瘤

5年肿瘤倍增时间预测无症状脑膜瘤长期自然史

The Impact of 5-Year Tumor Doubling Time to Predict the Subsequent Long-Term Natural History of Asymptomatic Meningiomas.
PubMed 文献 · World Neurosurg · 2021-05-18

本研究回顾性纳入201例影像学疑似颅内无症状脑膜瘤且前5年未治疗的患者,通过体积测量计算5年肿瘤倍增时间(5y-TdT),并分析其与后续长期自然史的关系。结果显示,出现症状并接受治疗者5y-TdT中位46.5个月,显著短于保持无症状者的216.3个月(P<0.001);5y-TdT≥98.8个月与<98.8个月者无进展生存期(PFS)差异显著(P<0.001)。

要点

  • 5y-TdT较短的无症状脑膜瘤更可能后续出现症状并需治疗。
  • 5y-TdT≥98.8个月与<98.8个月者PFS差异显著(P<0.001)。
  • 前5年未治疗的无症状脑膜瘤中,超20%患者15年内需治疗。

核心结论

  • 5y-TdT有助于识别无症状脑膜瘤中后续可能需要治疗的患者。

研究设计与样本

  • 回顾性研究,纳入201例影像学疑似颅内无症状脑膜瘤且前5年未治疗的患者。
  • 按后续病程分为三组:保持无症状组A(174例)、出现神经症状并治疗组B(8例)、预防性干预组C(19例)。
  • 通过体积测量初始5年病灶变化,计算5年肿瘤倍增时间(5y-TdT)。

主要发现

  • B组5y-TdT中位46.5个月,显著短于A组中位216.3个月(P<0.001)。
  • 5y-TdT≥98.8个月与<98.8个月者PFS差异显著(P<0.001)。
  • 合并B组与C组并以疾病进展或治疗为PFS终点时,超过20%患者15年内需治疗。

关键数值与推荐

  • 5y-TdT≥98.8个月与<98.8个月为PFS显著差异的分界值(P<0.001)。
  • B组5y-TdT中位46.5个月,A组中位216.3个月(P<0.001)。

临床怎么用

  • 对前5年未治疗的无症状脑膜瘤,可计算5y-TdT辅助判断后续治疗需求。
  • 5y-TdT较短者可能需更密切随访,以尽早发现症状进展或治疗指征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meningiomas are the most frequent primary brain tumors. The long-term natural history of asymptomatic meningiomas remains unclear and difficult to predict accurately, however. The purpose of this study was to determine the subsequent course of asymptomatic meningiomas preceded by 5 years of no treatment. METHODS: We retrospectively studied patients with radiologically suspected intracranial asymptomatic meningiomas preceded by 5 years of no treatment. We volumetrically measured the lesions' chronological changes during the initial 5 years to obtain the 5-year tumor doubling time (5y-TdT). RESULTS: A total of 201 cases met the inclusion criteria. They were further divided into 3 subgroups: those who remained asymptomatic (group A; 174 cases), those who developed neurological symptoms and underwent treatment (group B; 8 cases), and those who received intentional intervention for a preventative reason (group C; 19 cases). 5y-TdT of group B (median: 46.5 months) was significantly shorter than that of group A (median: 216.3 months) (P < 0.001). Progression-free survival (PFS) was significantly different between tumors that exhibited 5y-TdT ≥ 98.8 months and <98.8 months (P < 0.001). When we combined groups B and C and set the PFS endpoint as either disease progression or treatment, we found that more than 20% of patients would require treatment within 15 years. CONCLUSIONS: The present study revealed the subsequent course of asymptomatic meningiomas after 5 years of no treatment and demonstrated that 5y-TdT is useful to detect patients who may require treatment.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yamada S, Kinoshita M, Nakagawa T, et al. The Impact of 5-Year Tumor Doubling Time to Predict the Subsequent Long-Term Natural History of Asymptomatic Meningiomas. World Neurosurg. 2021. PMID: 34020064. doi:10.1016/j.wneu.2021.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。